NERV — Minerva Neurosciences, Inc.

Summary of Minerva Neurosciences Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2023, Minerva had approximately $36.1 million in cash, cash equivalents, and restricted cash, slightly down from $36.2 million at the end of 2022.
• Net Loss: The company reported a net loss of approximately $7 million for Q1 2023, translating to a net loss per share of $1.31, an improvement from a net loss of $9.8 million or $1.83 per share in Q1 2022.
• Research and Development (R&D) Expenses: R&D expenses decreased to $2.7 million from $5 million year-over-year, attributed to lower non-cash stock compensation and consultant fees.
• General and Administrative (G&A) Expenses: G&A expenses also decreased to $2.7 million from $3 million, primarily due to reduced non-cash stock compensation.

2. Strategic Updates and Business Highlights

• FDA Interaction: The FDA confirmed the filing of the New Drug Application (NDA) for roluperidone on April 27, 2023, with a standard review timeline and a PDUFA goal date of February 26, 2024. The FDA does not plan to hold an advisory committee for this application.
• Roluoperidone's Unique Position: Roluoperidone is positioned as a potential treatment for the negative symptoms of schizophrenia, a currently underserved area with no approved therapies in the U.S. The company emphasizes its unique mechanism of action and the potential for significant functional improvement in patients.
• Clinical Trial Data: The Phase 2b study met its primary endpoint, while the Phase 3 study showed nominal statistical significance for the 64 mg dose but did not meet the stringent criteria for declaring a positive finding for the 32 mg dose.

3. Forward Guidance and Outlook

• Cash Runway: The company believes its current cash position will be sufficient to meet anticipated capital requirements for at least the next 12 months.
• Market Strategy for Roluoperidone: Minerva is considering potential partnerships for the commercialization of roluperidone and is evaluating the need for hiring sales representatives based on the approval timeline.

4. Bad News, Challenges, or Points of Concern

• Regulatory Risks: The FDA has previously raised concerns regarding the NDA, including issues related to the conduct of clinical trials, which may still be under review. While the NDA has been filed, ongoing dialogue with the FDA is necessary to address any further questions.
• Statistical Significance: The Phase 3 study's results were not statistically significant for one of the doses, which could pose challenges in the approval process and market acceptance.
• Market Competition: The absence of approved treatments for negative symptoms is a positive, but the competitive landscape remains uncertain, particularly with other companies potentially developing similar therapies.

5. Notable Q&A Insights

• FDA Review Process: Management indicated that the FDA's decision to file the NDA was influenced by a detailed re-explanation of the data set during a formal dispute resolution meeting, rather than new data being added.
• Launch Strategy: The company is contemplating a partnership for the launch of roluperidone, suggesting that they may not proceed with a full-scale internal launch without a partner.
• Remaining Economics from Seltorexant: Minerva has approximately $95 million in remaining milestones from its agreement with Royalty Pharma, which includes milestones related to Phase 3 studies and regulatory approvals.

Overall, Minerva Neurosciences is positioned at a critical juncture with the NDA for roluperidone, highlighting both significant opportunities and challenges ahead in the regulatory landscape and market dynamics.